@article{b5656bf03f70421fb034d5c5f4a18775,
title = "A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy",
abstract = "Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.",
keywords = "Antimetabolites, Antineoplastic, Cytarabine, Female, Humans, Middle Aged, Ovarian Neoplasms, Antimetabolites, Antineoplastic, Cytarabine, Female, Humans, Middle Aged, Ovarian Neoplasms",
author = "S Pignata and F Amant and Giovanni Scambia and R Sorio and E Breda and W Rasch and K Hernes and C Pisano and K Leunen and Domenica Lorusso and L Cannella and I. Vergote",
year = "2011",
doi = "10.1007/s00280-011-1735-4",
language = "English",
volume = "68",
pages = "1347--1353",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag Germany:Tiergartenstrasse 17, D 69121 Heidelberg Germany:011 49 6221 3450, EMAIL:
[email protected], INTERNET: http://www.springer.de, Fax: 011 49 6221 345229",
}